Legal status | |
---|---|
Legal status | |
Identifiers | |
| |
PubChem CID | |
ChemSpider | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C28H30ClN3O3 |
Molar mass | 492.02 g·mol−1 |
3D model (JSmol) | |
| |
|
FGI-104 is the name of an experimental broad-spectrum antiviral drug, with activity against a range of viruses including hepatitis B, hepatitis C, HIV, Ebola virus, and Venezuelan equine encephalitis virus. [1]
The drug acts by inhibiting the protein TSG101, which transports newly manufactured virions to the exterior of an infected cell, thus breaking the replication cycle of the virus. In pre-clinical studies, FGI-104 has been shown to protect mice from Ebola virus disease.[2][3]